283 related articles for article (PubMed ID: 28194436)
1. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.
Lee LH; Gasilina A; Roychoudhury J; Clark J; McCormack FX; Pressey J; Grimley MS; Lorsbach R; Ali S; Bailey M; Stephens P; Ross JS; Miller VA; Nassar NN; Kumar AR
JCI Insight; 2017 Feb; 2(3):e89473. PubMed ID: 28194436
[TBL] [Abstract][Full Text] [Related]
2. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
[TBL] [Abstract][Full Text] [Related]
3. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
4. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
[TBL] [Abstract][Full Text] [Related]
5. Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
Azorsa DO; Lee DW; Wai DH; Bista R; Patel AR; Aleem E; Henry MM; Arceci RJ
Pediatr Blood Cancer; 2018 Sep; 65(9):e27237. PubMed ID: 29768711
[TBL] [Abstract][Full Text] [Related]
6. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
7. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
Johnson AS; Crandall H; Dahlman K; Kelley MC
J Am Coll Surg; 2015 Apr; 220(4):581-93.e1. PubMed ID: 25797743
[TBL] [Abstract][Full Text] [Related]
8. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
10. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
[TBL] [Abstract][Full Text] [Related]
11. Dabrafenib and trametinib for the treatment of non-small cell lung cancer.
Kelly RJ
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1063-1068. PubMed ID: 30198802
[TBL] [Abstract][Full Text] [Related]
12. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
13. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
Nelson DS; van Halteren A; Quispel WT; van den Bos C; Bovée JV; Patel B; Badalian-Very G; van Hummelen P; Ducar M; Lin L; MacConaill LE; Egeler RM; Rollins BJ
Genes Chromosomes Cancer; 2015 Jun; 54(6):361-8. PubMed ID: 25899310
[TBL] [Abstract][Full Text] [Related]
14. BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.
Johnson DB; Childress MA; Chalmers ZR; Frampton GM; Ali SM; Rubinstein SM; Fabrizio D; Ross JS; Balasubramanian S; Miller VA; Stephens PJ; Sosman JA; Lovly CM
Pigment Cell Melanoma Res; 2018 May; 31(3):432-436. PubMed ID: 29171936
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.
Cournoyer E; Ferrell J; Sharp S; Ray A; Jordan M; Dandoy C; Grimley M; Roy S; Lorsbach R; Merrow AC; Nelson A; Bartlett A; Picarsic J; Kumar A
Haematologica; 2024 Apr; 109(4):1137-1148. PubMed ID: 37731389
[TBL] [Abstract][Full Text] [Related]
16. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.
Hyman DM; Diamond EL; Vibat CR; Hassaine L; Poole JC; Patel M; Holley VR; Cabrilo G; Lu TT; Arcila ME; Chung YR; Rampal R; Lacouture ME; Rosen N; Meric-Bernstam F; Baselga J; Kurzrock R; Erlander MG; Janku F; Abdel-Wahab O
Cancer Discov; 2015 Jan; 5(1):64-71. PubMed ID: 25324352
[TBL] [Abstract][Full Text] [Related]
17. Challenges of targeting
Smith-Cohn M; Davidson C; Colman H; Cohen AL
CNS Oncol; 2019 Dec; 8(4):CNS48. PubMed ID: 31818130
[No Abstract] [Full Text] [Related]
18. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
19. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
Corcoran RB; Atreya CE; Falchook GS; Kwak EL; Ryan DP; Bendell JC; Hamid O; Messersmith WA; Daud A; Kurzrock R; Pierobon M; Sun P; Cunningham E; Little S; Orford K; Motwani M; Bai Y; Patel K; Venook AP; Kopetz S
J Clin Oncol; 2015 Dec; 33(34):4023-31. PubMed ID: 26392102
[TBL] [Abstract][Full Text] [Related]
20. Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.
Pervere LM; Rakshit S; Schrock AB; Miller VA; Ali SM; Velcheti V
Clin Lung Cancer; 2017 May; 18(3):e211-e213. PubMed ID: 28024926
[No Abstract] [Full Text] [Related]
[Next] [New Search]